Literature DB >> 11456289

Inhibition of insulin release by urotensin II--a study on the perfused rat pancreas.

R A Silvestre1, J Rodríguez-Gallardo, E M Egido, J Marco.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11456289     DOI： 10.1055/s-2001-15414

Source DB:  PubMed          Journal:  Horm Metab Res        ISSN： 0018-5043            Impact factor:   2.936


× No keyword cloud information.
  12 in total

1.  Molecular and pharmacological characterization of genes encoding urotensin-II peptides and their cognate G-protein-coupled receptors from the mouse and monkey.

Authors:  Nabil A Elshourbagy; Stephen A Douglas; Usman Shabon; Stephen Harrison; Graham Duddy; Jan L Sechler; Zhaohui Ao; Beverly E Maleeff; Diane Naselsky; Jyoti Disa; Nambi V Aiyar
Journal:  Br J Pharmacol       Date:  2002-05       Impact factor: 8.739

2.  GSK1562590, a slowly dissociating urotensin-II receptor antagonist, exhibits prolonged pharmacodynamic activity ex vivo.

Authors:  D J Behm; N V Aiyar; A R Olzinski; J J McAtee; M A Hilfiker; J W Dodson; S E Dowdell; G Z Wang; K B Goodman; C A Sehon; M R Harpel; R N Willette; M J Neeb; C A Leach; S A Douglas
Journal:  Br J Pharmacol       Date:  2010-09       Impact factor: 8.739

3.  Role of urotensin II gene in genetic susceptibility to Type 2 diabetes mellitus in Japanese subjects.

Authors:  Z Wenyi; S Suzuki; M Hirai; Y Hinokio; Y Tanizawa; A Matsutani; J Satoh; Y Oka
Journal:  Diabetologia       Date:  2003-06-27       Impact factor: 10.122

4.  Deletion of the UT receptor gene results in the selective loss of urotensin-II contractile activity in aortae isolated from UT receptor knockout mice.

Authors:  David J Behm; Stephen M Harrison; Zhaohui Ao; Kristeen Maniscalco; Susan J Pickering; Evelyn V Grau; Tina N Woods; Robert W Coatney; Christopher P A Doe; Robert N Willette; Douglas G Johns; Stephen A Douglas
Journal:  Br J Pharmacol       Date:  2003-05       Impact factor: 8.739

5.  Effect of the urotensin-II receptor antagonist palosuran on secretion of and sensitivity to insulin in patients with Type 2 diabetes mellitus.

Authors:  Patricia N Sidharta; Klaus Rave; Lutz Heinemann; Eleonora Chiossi; Stephan Krähenbühl; Jasper Dingemanse
Journal:  Br J Clin Pharmacol       Date:  2009-10       Impact factor: 4.335

6.  No effect on central or peripheral blood pressure of systemic urotensin II infusion in humans.

Authors:  Jonathan T Affolter; David E Newby; Ian B Wilkinson; Matthew J Winter; Richard J Balment; David J Webb
Journal:  Br J Clin Pharmacol       Date:  2002-12       Impact factor: 4.335

7.  Identification and pharmacological characterization of native, functional human urotensin-II receptors in rhabdomyosarcoma cell lines.

Authors:  Stephen A Douglas; Diane Naselsky; Zhaohui Ao; Jyoti Disa; Christopher L Herold; Frank Lynch; Nambi V Aiyar
Journal:  Br J Pharmacol       Date:  2004-06-21       Impact factor: 8.739

8.  A closer look at the role of urotensin II in the metabolic syndrome.

Authors:  Pierre-Olivier Barrette; Adel Giaid Schwertani
Journal:  Front Endocrinol (Lausanne)       Date:  2012-12-28       Impact factor: 5.555

9.  Association analysis of urotensin II gene (UTS2) and flanking regions with biochemical parameters related to insulin resistance.

Authors:  María E Sáez; Tarik Smani; Reposo Ramírez-Lorca; Ignacio Díaz; Manuel Serrano-Ríos; Agustín Ruiz; Antonio Ordoñez
Journal:  PLoS One       Date:  2011-04-29       Impact factor: 3.240

10.  Potential Clinical Implications of the Urotensin II Receptor Antagonists.

Authors:  Philip Tsoukas; Emilie Kane; Adel Giaid
Journal:  Front Pharmacol       Date:  2011-07-22       Impact factor: 5.810
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.